454 related articles for article (PubMed ID: 25998860)
1. The histone methyltransferase EZH2 promotes mammary stem and luminal progenitor cell expansion, metastasis and inhibits estrogen receptor-positive cellular differentiation in a model of basal breast cancer.
Wu J; Crowe DL
Oncol Rep; 2015 Jul; 34(1):455-60. PubMed ID: 25998860
[TBL] [Abstract][Full Text] [Related]
2. The methyltransferase EZH2 is not required for mammary cancer development, although high EZH2 and low H3K27me3 correlate with poor prognosis of ER-positive breast cancers.
Bae WK; Yoo KH; Lee JS; Kim Y; Chung IJ; Park MH; Yoon JH; Furth PA; Hennighausen L
Mol Carcinog; 2015 Oct; 54(10):1172-80. PubMed ID: 25043748
[TBL] [Abstract][Full Text] [Related]
3. Polycomb group gene Ezh2 regulates mammary gland morphogenesis and maintains the luminal progenitor pool.
Michalak EM; Nacerddine K; Pietersen A; Beuger V; Pawlitzky I; Cornelissen-Steijger P; Wientjens E; Tanger E; Seibler J; van Lohuizen M; Jonkers J
Stem Cells; 2013 Sep; 31(9):1910-20. PubMed ID: 23712803
[TBL] [Abstract][Full Text] [Related]
4. EZH2 promotes a bi-lineage identity in basal-like breast cancer cells.
Granit RZ; Gabai Y; Hadar T; Karamansha Y; Liberman L; Waldhorn I; Gat-Viks I; Regev A; Maly B; Darash-Yahana M; Peretz T; Ben-Porath I
Oncogene; 2013 Aug; 32(33):3886-95. PubMed ID: 22986524
[TBL] [Abstract][Full Text] [Related]
5. The JMJD3 Histone Demethylase and the EZH2 Histone Methyltransferase in Prostate Cancer.
Daures M; Ngollo M; Judes G; Rifaï K; Kemeny JL; Penault-Llorca F; Bignon YJ; Guy L; Bernard-Gallon D
OMICS; 2016 Feb; 20(2):123-5. PubMed ID: 26871869
[No Abstract] [Full Text] [Related]
6. Ezh2 regulates differentiation and function of natural killer cells through histone methyltransferase activity.
Yin J; Leavenworth JW; Li Y; Luo Q; Xie H; Liu X; Huang S; Yan H; Fu Z; Zhang LY; Zhang L; Hao J; Wu X; Deng X; Roberts CW; Orkin SH; Cantor H; Wang X
Proc Natl Acad Sci U S A; 2015 Dec; 112(52):15988-93. PubMed ID: 26668377
[TBL] [Abstract][Full Text] [Related]
7. Epigenetic regulation of cell adhesion and communication by enhancer of zeste homolog 2 in human endothelial cells.
Dreger H; Ludwig A; Weller A; Stangl V; Baumann G; Meiners S; Stangl K
Hypertension; 2012 Nov; 60(5):1176-83. PubMed ID: 22966008
[TBL] [Abstract][Full Text] [Related]
8. Sox4 is a master regulator of epithelial-mesenchymal transition by controlling Ezh2 expression and epigenetic reprogramming.
Tiwari N; Tiwari VK; Waldmeier L; Balwierz PJ; Arnold P; Pachkov M; Meyer-Schaller N; Schübeler D; van Nimwegen E; Christofori G
Cancer Cell; 2013 Jun; 23(6):768-83. PubMed ID: 23764001
[TBL] [Abstract][Full Text] [Related]
9. BRCA1 and EZH2 cooperate in regulation of prostate cancer stem cell phenotype.
Gorodetska I; Lukiyanchuk V; Peitzsch C; Kozeretska I; Dubrovska A
Int J Cancer; 2019 Dec; 145(11):2974-2985. PubMed ID: 30968962
[TBL] [Abstract][Full Text] [Related]
10. EZH2 variants differentially regulate polycomb repressive complex 2 in histone methylation and cell differentiation.
Mu W; Starmer J; Yee D; Magnuson T
Epigenetics Chromatin; 2018 Dec; 11(1):71. PubMed ID: 30522506
[TBL] [Abstract][Full Text] [Related]
11. Prognostic impact of the cancer stem cell related markers ALDH1 and EZH2 in triple negative and basal-like breast cancers.
De Brot M; Rocha RM; Soares FA; Gobbi H
Pathology; 2012 Jun; 44(4):303-12. PubMed ID: 22544210
[TBL] [Abstract][Full Text] [Related]
12. Targeted overexpression of EZH2 in the mammary gland disrupts ductal morphogenesis and causes epithelial hyperplasia.
Li X; Gonzalez ME; Toy K; Filzen T; Merajver SD; Kleer CG
Am J Pathol; 2009 Sep; 175(3):1246-54. PubMed ID: 19661437
[TBL] [Abstract][Full Text] [Related]
13. In utero exposure to diethylstilbestrol (DES) or bisphenol-A (BPA) increases EZH2 expression in the mammary gland: an epigenetic mechanism linking endocrine disruptors to breast cancer.
Doherty LF; Bromer JG; Zhou Y; Aldad TS; Taylor HS
Horm Cancer; 2010 Jun; 1(3):146-55. PubMed ID: 21761357
[TBL] [Abstract][Full Text] [Related]
14. The polycomb group protein enhancer of zeste 2 is a novel therapeutic target for cervical cancer.
Ding M; Zhang H; Li Z; Wang C; Chen J; Shi L; Xu D; Gao Y
Clin Exp Pharmacol Physiol; 2015 May; 42(5):458-64. PubMed ID: 25739318
[TBL] [Abstract][Full Text] [Related]
15. Expression of a constitutively active prolactin receptor causes histone trimethylation of the p53 gene in breast cancer.
Tan D; Tang P; Huang J; Zhang J; Zhou W; Walker AM
Chin Med J (Engl); 2014; 127(6):1077-83. PubMed ID: 24622438
[TBL] [Abstract][Full Text] [Related]
16. Epigenetic reprogramming by tumor-derived EZH2 gain-of-function mutations promotes aggressive 3D cell morphologies and enhances melanoma tumor growth.
Barsotti AM; Ryskin M; Zhong W; Zhang WG; Giannakou A; Loreth C; Diesl V; Follettie M; Golas J; Lee M; Nichols T; Fan C; Li G; Dann S; Fantin VR; Arndt K; Verhelle D; Rollins RA
Oncotarget; 2015 Feb; 6(5):2928-38. PubMed ID: 25671303
[TBL] [Abstract][Full Text] [Related]
17. EZH2, JMJD3, and UTX epigenetically regulate hepatic plasticity inducing retro-differentiation and proliferation of liver cells.
Pediconi N; Salerno D; Lupacchini L; Angrisani A; Peruzzi G; De Smaele E; Levrero M; Belloni L
Cell Death Dis; 2019 Jul; 10(7):518. PubMed ID: 31285428
[TBL] [Abstract][Full Text] [Related]
18. Role of EZH2 in cancer stem cells: from biological insight to a therapeutic target.
Wen Y; Cai J; Hou Y; Huang Z; Wang Z
Oncotarget; 2017 Jun; 8(23):37974-37990. PubMed ID: 28415635
[TBL] [Abstract][Full Text] [Related]
19. EZH2 expands breast stem cells through activation of NOTCH1 signaling.
Gonzalez ME; Moore HM; Li X; Toy KA; Huang W; Sabel MS; Kidwell KM; Kleer CG
Proc Natl Acad Sci U S A; 2014 Feb; 111(8):3098-103. PubMed ID: 24516139
[TBL] [Abstract][Full Text] [Related]
20. Regulation of Retinal Development via the Epigenetic Modification of Histone H3.
Watanabe S; Murakami A
Adv Exp Med Biol; 2016; 854():635-41. PubMed ID: 26427469
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]